Physician profile
Michael Caughron
NPI 1780071506
$1,391.45
in general payments reported to CMS, 2019-2025
18 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $372 · 2023: $173 · 2024: $551 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $344.64 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $323.52 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $170.41 | 2024-2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $115.60 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $97.62 | 2022-2023 | Shingrix, Arexvy |
| Amgen INC. | $58.59 | 2022-2023 | Prolia |
| Sanofi Pasteur INC. | $54.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $36.71 | 2021-2024 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.39 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $24.86 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.06 | 2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.05 | 2024 | Jardiance |
| Abbvie INC. | $17.21 | 2021 | |
| Exact Sciences Corporation | $16.61 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.03 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $14.25 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $12.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caughron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.